困难梭状芽孢桿菌传染病（CDI）：市场展望、流行病学、竞争格局、市场预测报告（2025-2035年）

市场概览

• 儘管患者数量相对稳定，但受新治疗方法的引入推动，法国 CDI 市场预计将出现温和增长，从 2025 年的 7800 万美元增长到 2035 年的 1.17 亿美元。
• 患者数量成长有限（年复合成长率为 0.4-0.5%），显示市场扩张主要受以下因素驱动：
• 增加针对復发的先进治疗方法的使用
• 逐步过渡到基于微生物组的治疗和辅助性治疗
• 目前市场收入主要由标准抗生素疗法（例如万古霉素、非达霉素）支撑，这些疗法仍然是急性护理的基础。
• 未来的成长将取决于创新治疗方法的广泛应用，这些疗法专注于预防復发和改善长期疗效，尤其是在高风险患者群体中。

困难梭状芽孢桿菌传染病（CDI）概述

困难梭状芽孢桿菌传染病（CDI）是由艰难梭菌引起的严重的毒素介导的胃肠道疾病。艰难梭菌是一种革兰氏阳性、厌氧、产芽孢的细菌，主要在肠道菌丛因使用广效抗生素而遭到破坏后定植于肠道。此疾病主要由高抗药性芽孢的粪口传播以及强效外毒素（特别是毒素A和B）的产生引起，这些毒素可导致上皮损伤、发炎和黏膜损伤。

临床上，艰难梭菌感染的严重程度频谱很大，从轻度至中度腹泻到严重的危及生命的併发症，例如假膜性肠炎、中毒性巨结肠、肠穿孔和败血症。它仍然是全球医疗相关感染的主要原因之一，对老年人、免疫力缺乏者和住院患者的影响尤其显着。

艰难梭菌感染 (CDI) 的一个显着特征是其高復发率，这源于持续存在的孢子和治疗后肠道菌群恢復不完全。这极大地影响了治疗方法。虽然非达霉素和口服万古霉素等标准抗生素仍是急性期治疗的基础，但治疗策略正朝着预防復发的方向发展。这包括肠道菌丛重建疗法，例如毒素中和单株抗体（如贝洛妥昔单抗）、粪便微生物移植 (FMT) 和新型生物製药。这些疗法旨在恢復定植抵抗力并降低復发风险。

主要亮点

• CDI 作为一种医疗保健相关感染疾病，给法国带来了沉重的负担，其中大多数病例发生在住院患者和老年人中。
• 预计法国住院的 CDI 病例数将从 2025 年的 63,000 例增加到 2035 年的 65,900 例，反映出人口老化和医疗保健接触增加所导致的逐步增长（年复合增长率为 0.4%–0.5%）。
• 高復发率（20-30%）仍然是最重大的临床挑战，导致反覆住院和医疗负担加重。
• 随着人们对预防復发和恢復微生物群疗法的关注度不断提高，治疗方法有望逐渐摆脱对传统抗生素的依赖。

格式化和更新讯息

• 详细报告（PDF）
• 市场预测模型（基于微软Excel）
• 流行病学数据（MS Excel，互动式工具）
• 高阶主管洞察（PPT简报）
• 其他功能：定期更新、自订和顾问支援。
• 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

• 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
• 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
• 未来十年市场收入和病患份额的预测是多少？
• 哪些因素对市场趋势影响最大？
• 受访专家对目前和新兴的治疗方法有何看法？
• 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
• 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
• 为确保药物核准并顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

• G8
  • 我们
  • EU5
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
  • 日本
  • 中国

大公司

• Acurx Pharmaceuticals Inc.
• Actelion
• Lumen Bioscience, Inc.
• AstraZeneca
• Crestone, Inc
• Vedanta Biosciences, Inc.
• Gateway Pharmaceutical LLC

目录

第一章：主要调查结果及分析师说明

• 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

• 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

• 重点
• 发病率/盛行率
• 已确诊并接受药物治疗的患者人数
• 合併症
• 其他相关患者群

第四章 市场规模及预测

• 重点
• 市场驱动因素与限制因素
• 按药物类别分類的趋势
• 各国具体趋势

第五章 竞争情势

• 目前的治疗方法
• 重点
• 诊断和治疗过程/演算法
• 主要治疗方法概述及KOL洞察
• 新兴治疗方法
• 重点
• 值得关注的后期新治疗方法－概述、市场上市预期及KOL洞察
• 值得关注的早期研发管线

第六章：未满足的需求与TPP分析

• 主要未满足的需求以及透过新兴治疗方法实现的未来可能性
• TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

Clostridium Difficile Infection (CDI) Market Outlook

Thelansis's "Clostridium Difficile Infection (CDI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Clostridium Difficile Infection treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Clostridium Difficile Infection (CDI) Overview

Clostridium difficile Infection (CDI) is a serious, toxin-mediated gastrointestinal disease caused by Clostridioides difficile, a Gram-positive, anaerobic, spore-forming bacterium that colonizes the gut following disruption of the normal intestinal microbiota-most commonly due to broad-spectrum antibiotic exposure. The disease is primarily driven by fecal-oral transmission of highly resilient spores and the production of potent exotoxins, notably Toxin A and Toxin B, which induce epithelial damage, inflammation, and mucosal injury.

Clinically, CDI presents across a wide severity spectrum, ranging from mild-to-moderate diarrhea to severe and life-threatening complications, including pseudomembranous colitis, Toxic Megacolon, bowel perforation, and sepsis. It remains a leading cause of healthcare-associated infections globally, particularly impacting elderly, immunocompromised, and hospitalized populations.

A defining characteristic of CDI is its high recurrence rate, driven by persistent spores and incomplete microbiome recovery following treatment. This has significantly shaped the therapeutic landscape. While standard-of-care antibiotics such as fidaxomicin and oral vancomycin remain the cornerstone for acute management, treatment strategies have evolved toward recurrence prevention. This includes toxin-neutralizing monoclonal antibodies (e.g., bezlotoxumab) and microbiome restoration approaches such as fecal microbiota transplantation (FMT) and emerging live biotherapeutic products, which aim to restore colonization resistance and reduce relapse risk.

Key Highlights

• CDI represents a significant healthcare-associated infection burden in France, with the majority of cases occurring in hospitalized and elderly populations.
• Hospitalized CDI cases in France are projected to increase from 63.0K in 2025 to 65.9K by 2035, reflecting a modest growth trajectory (0.4-0.5% CAGR) driven by aging population and healthcare exposure.
• High recurrence rates (20-30%) continue to be the most critical clinical challenge, contributing to repeated hospitalizations and increased healthcare burden.
• Growing focus on recurrence prevention and microbiome restoration therapies is expected to gradually shift treatment practices beyond conventional antibiotics.

Market Overview

• The France CDI market is projected to grow from $78M in 2025 to $117M by 2035, reflecting moderate growth driven by adoption of newer therapies despite a relatively stable patient base.
• Limited patient growth (0.4-0.5% CAGR) indicates that market expansion is primarily driven by:
• Increased use of premium therapies targeting recurrence
• Gradual shift toward microbiome-based and adjunctive treatments
• Current market revenues are largely driven by standard antibiotic therapies (e.g., vancomycin, fidaxomicin), which remain the backbone of acute treatment.
• Future growth will depend on the uptake of innovative therapies focused on reducing recurrence and improving long-term outcomes, particularly in high-risk patient populations.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Acurx Pharmaceuticals Inc.
• Actelion
• Lumen Bioscience, Inc.
• AstraZeneca
• Crestone, Inc
• Vedanta Biosciences, Inc.
• Gateway Pharmaceutical LLC

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)